Ingredients and medical food company, Enzymotec Ltd (NASDAQ:ENZY), is plummeting in the market by a high of 28.57% after the company reported its first quarter unaudited financial results. During the quarter, the company signed a settlement and license agreement with Neptune Technologies & Bio resources. It also completed the repayment of its long-term loan subject to financial and other covenants. Enzymotec Ltd (NASDAQ:ENZY) net profit margin is 11.70% and weekly performance is -29.16%. On last trading day company shares ended up $13.75. Analysts mean target price for the company is $29.00. Enzymotec Ltd (NASDAQ:ENZY) distance from 50-day simple moving average (SMA50) is -38.58%.
On 12 May, MELA Sciences, Inc. (NASDAQ:MELA), developer of the MelaFind® system, an optical diagnostic device approved for use in the United States and the European Union to assist dermatologists in melanoma diagnosis, announced results for its fiscal 2014 first quarter (Q1’14) ended March 31, 2014. MELA Sciences reported a Q1’14 net loss of approximately $8.0 million, or $0.16 per share, compared with a net loss of approximately $6.5 million, or $0.17 per share for the comparable period last year. Included in the Q1’14 financial results were liquidated damages of approximately $3.4 million incurred and paid in connection with the Company’s financing completed in February 2014. MELA Sciences Inc (NASDAQ:MELA) shares fell -14.63% in last trading session and ended the day on $0.444. MELA return on assets is -121.00%. MELA Sciences Inc (NASDAQ:MELA) quarterly performance is -39.73%.
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, announced financial results for the first quarter ended March 31, 2014, and provided updates on its clinical development programs. Net loss for first quarter 2014 was $5.2 million compared with $2.3 million for first quarter 2013. Research and development expenses were $3.7 million for first quarter 2014 compared with $1.0 million for first quarter 2013. General and administrative expenses were $1.6 million for first quarter 2014 compared with $0.7 million for first quarter 2013. Conatus Pharmaceuticals Inc (NASDAQ:CNAT) shares moved up 3.93% in last trading session and was closed at $5.55, while trading in range of $5.06 – $5.68. Conatus Pharmaceuticals Inc (NASDAQ:CNAT) year to date (YTD) performance is -13.95 %.
MEI Pharma, Inc (NASDAQ:MEIP) an oncology company focused on the clinical development of novel therapies for cancer, announced that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present investor conferences: The UBS Global Healthcare Conference on Tuesday, May 20, 2014 at 9:00 a.m. Eastern time from the Sheraton New York Times Square Hotel. MEI Pharma Inc (NASDAQ:MEIP) ended the last trading day at $6.43. Company weekly volatility is calculated as 8.57% and price to cash ratio as 2.32. MEI Pharma Inc (NASDAQ:MEIP) showed a negative weekly performance of -4.46%.